Pages that link to "Q87087951"

The following pages link to Improved long-term survival in multiple myeloma up to the age of 80 years (Q87087951):

Displaying 43 items.

• Multiple myeloma epidemiology and survival: A unique malignancy (Q30239771) (← links)
• Exploring Big Data in Hematological Malignancies: Challenges and Opportunities (Q31095966) (← links)
• Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen (Q33434435) (← links)
• Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients (Q34798105) (← links)
• Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy (Q35032345) (← links)
• Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program (Q35907586) (← links)
• ESRD due to Multiple Myeloma in the United States, 2001-2010. (Q36849170) (← links)
• Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study (Q37216305) (← links)
• Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma (Q37327618) (← links)
• History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. (Q37580855) (← links)
• Update on second primary malignancies in multiple myeloma: a focused review (Q38178031) (← links)
• Minimal residual disease in multiple myeloma: bringing the bench to the bedside (Q38333145) (← links)
• New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib (Q38598891) (← links)
• New Approaches to Molecular Imaging of Multiple Myeloma (Q38626360) (← links)
• High-throughput sequencing for noninvasive disease detection in hematologic malignancies. (Q38672646) (← links)
• Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics (Q38740697) (← links)
• Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting (Q39024142) (← links)
• The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study (Q40309114) (← links)
• Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis (Q40594905) (← links)
• Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations (Q41602673) (← links)
• Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study (Q42180809) (← links)
• Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. (Q42234608) (← links)
• Health-related quality of life in patients with multiple myeloma--does it matter? (Q42848332) (← links)
• New developments in diagnosis, prognosis, and assessment of response in multiple myeloma (Q43402624) (← links)
• Early mortality in multiple myeloma (Q45412209) (← links)
• Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-κB pathway (Q47105619) (← links)
• Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR). (Q47198067) (← links)
• Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis (Q47236245) (← links)
• Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. (Q52575333) (← links)
• Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. (Q52641886) (← links)
• Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy. (Q54970050) (← links)
• Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study (Q57174093) (← links)
• Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution (Q64083182) (← links)
• Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States (Q89777843) (← links)
• Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial (Q90012167) (← links)
• The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma (Q90312898) (← links)
• Lenalidomide-based response-adapted therapy for older adults without high risk myeloma (Q90476372) (← links)
• Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry (Q90681569) (← links)
• Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma (Q91762986) (← links)
• Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma (Q92154272) (← links)
• Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study (Q93209619) (← links)
• Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma (Q98784820) (← links)
• Will the reclassification of multiple myeloma change how people are treated? (Q102389129) (← links)